Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Operating Expenses (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Operating Expenses for 13 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 554.2% year-over-year to $2.2 million, compared with a TTM value of $7.2 million through Dec 2025, up 44.17%, and an annual FY2025 reading of $7.2 million, up 37.15% over the prior year.
  • Operating Expenses was $2.2 million for Q4 2025 at Abvc Biopharma, up from $2.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $6.4 million in Q4 2021 and bottomed at $336124.0 in Q4 2024.
  • Average Operating Expenses over 5 years is $2.3 million, with a median of $2.1 million recorded in 2021.
  • The sharpest move saw Operating Expenses tumbled 89.16% in 2023, then skyrocketed 554.2% in 2025.
  • Year by year, Operating Expenses stood at $6.4 million in 2021, then tumbled by 46.05% to $3.5 million in 2022, then crashed by 89.16% to $374794.0 in 2023, then dropped by 10.32% to $336124.0 in 2024, then surged by 554.2% to $2.2 million in 2025.
  • Business Quant data shows Operating Expenses for ABVC at $2.2 million in Q4 2025, $2.0 million in Q3 2025, and $2.3 million in Q2 2025.